Krka DDLTS:0HLK 78 FCF Margin % is 11.98% as of Mar. 2026, which is 22% below its 10-year median of 15.39. GuruFocus rates LTS:0HLK with a GF Score™ of 78/100 and a GF Value™ of €38.09 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Krka DD ranks better than 84.4% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Krka DD's Free Cash Flow for the
three
months ended in Mar. 2026 was €68 Mil. Krka DD's Revenue for the
three
months ended in Mar. 2026 was €566 Mil. Therefore, Krka DD's FCF Margin % for the quarter that ended in Mar. 2026 was 11.98%.
The historical rank and industry rank for Krka DD's FCF Margin % or its related term are showing as below:
LTS:0HLK'
s FCF Margin % Range Over the Past 10 Years
Min: 4.87 Med: 15.39 Max: 21.71
Current: 16.91
During the past 13 years, the highest FCF Margin % of Krka DD was 21.71%. The lowest was 4.87%. And the median was 15.39%.
LTS:0HLK's FCF Margin % is ranked better than 84.4% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs LTS:0HLK: 16.91
Krka DD FCF Margin % Related Terms
Krka DD FCF Margin % Historical Data
* Premium members only.
The historical data trend for Krka DD's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Krka DD's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a FCF Margin % of 11.98% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Krka DD and its competitors. This is 22% below median its historical median of 15.39. Over the past decade, Krka DD's FCF Margin % has ranged from 4.87 to 21.71. According to the industry distribution chart, Krka DD ranks #149 out of 955 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Krka DD's FCF Margin % too high?
Krka DD's current FCF Margin % of 11.98% is 22% below median its 10-year median of 15.39. Over the past 10 years, this metric has ranged from a low of 4.87 to a high of 21.71. The Drug Manufacturers industry median FCF Margin % is 2.51. Krka DD's value of 11.98% is 377.3% above this industry median. Based on the distribution chart, Krka DD ranks #149 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #149 out of 955 companies for FCF Margin %. This places Krka DD in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Krka DD's value of 11.98% is 377.3% above this benchmark. Historically, Krka DD's own FCF Margin % has ranged from 4.87 to 21.71 over the past decade. While the company's 10-year median is 15.39 vs. the industry median of 2.51, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current FCF Margin % of 11.98% is 377.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current FCF Margin % is 11.98%, which is 22% below median its own 10-year median of 15.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €38.09, compared to a current price of €64.80 — trading 70.1% above its estimated fair value. The current FCF Margin % is 11.98%, which is 22% below median its 10-year median of 15.39 and 377.3% above the Drug Manufacturers industry median of 2.51. Krka DD's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current FCF Margin % is 11.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 70.1% above its estimated GF Value™ of €38.09.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
FCF Margin %: 11.98% (22% below median its 10-year median of 15.39)
GF Value™: €38.09 vs. price of €64.80 (70.1% above fair value)
Industry Position: 377.3% above the Drug Manufacturers median (#149 of 955)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
78GF Score
Get the complete analysis for LTS:0HLK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
